MétaCan
Menu
Back to cohort
Record W4416228555 · doi:10.1111/jdv.70147

From reactive to predictive: Advancing biologic dosing in dermatology

2025· article· en· W4416228555 on OpenAlexaff
Anke Eylenbosch, Rani Soenen, Catherine Smith, Joseph F. Standing, Satveer K. Mahil, Jo Lambert

Bibliographic record

VenueJournal of the European Academy of Dermatology and Venereology · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicPsoriasis: Treatment and Pathogenesis
Canadian institutionsInstitute of Infection and Immunity
FundersFonds Wetenschappelijk OnderzoekBritish Skin Foundation
KeywordsDosingTherapeutic drug monitoringPharmacogenomicsDrugPopulationAdverse effectPrecision medicinePharmacokinetics

Abstract

fetched live from OpenAlex

Biologic therapies are targeted immunomodulators that have revolutionised the treatment of chronic inflammatory dermatoses, including psoriasis, hidradenitis suppurativa and atopic dermatitis, offering high efficacy and safety for moderate-to-severe disease. However, standardised dosing regimens fail to account for inter-individual heterogeneity, leading to non-optimal drug exposure in certain patients. This may, in part, explain why primary non-response, secondary loss of response or adverse effects are observed in real-world practice. While empirical off-label adjustments are commonly employed, data-driven dosing optimisation may enable better disease control and reduce the burden of lifelong biologic treatment by avoiding excessive dosing. Therapeutic drug monitoring (TDM) involves adjusting doses based on serum drug concentrations to maintain therapeutic ranges, relying on established dose-exposure-response correlations. Although TDM provides reactive or proactive optimisation approaches, its threshold-based adjustments are limited by an inability to predict individual pharmacokinetic variability or future clinical outcomes. Model-informed precision dosing (MIPD) represents an evolution beyond conventional TDM by integrating population pharmacokinetic-pharmacodynamic models, patient-specific characteristics and Bayesian forecasting to deliver personalised, adaptive dosing recommendations. This approach captures inter-individual variability while linking serum drug concentrations to clinical response, enabling proactive dose adjustments using sparse or non-steady-state data. Emerging digital tools, point-of-care testing and integration of pharmacogenomics and biomarker profiling are expected to enhance MIPD's precision and accessibility. Once implemented in routine care, MIPD has the potential to transform biologic therapy dosing using a dynamic, patient-centric system that maximises clinical response, minimises overtreatment and supports sustainable healthcare delivery.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.030
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.008
Threshold uncertainty score0.044

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.030
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.002
Science and technology studies0.0000.002
Scholarly communication0.0060.006
Open science0.0030.003
Research integrity0.0030.006
Insufficient payload (model declined to judge)0.0040.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.263
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the European Academy of Dermatology and VenereologySame topicPsoriasis: Treatment and PathogenesisFrench-language works237,207